Shangya Technology (6130) reported revenue of NT$17.8 million for Oct 2026, +55.4% year on year and +69.1% from the previous month. Revenue for Jan–Oct 2026 was NT$153.1 million (+18.7% year on year).
In Oct 2026, it ranked No. 128 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$17.8 million | +55.4% | +69.1% |
| Sep 2026 | NT$10.5 million | -26.3% | -21.6% |
| Aug 2026 | NT$13.4 million | +1.4% | -40.1% |
| Jul 2026 | NT$22.4 million | +92.7% | +26.0% |
| Jun 2026 | NT$17.8 million | +70.9% | +4.1% |
| May 2026 | NT$17.1 million | +35.7% | +15.7% |
| Apr 2026 | NT$14.8 million | -6.0% | +3.4% |
| Mar 2026 | NT$14.3 million | +31.9% | +79.0% |
| Feb 2026 | NT$8 million | -62.2% | -53.3% |
| Jan 2026 | NT$17.1 million | +120.5% | +29.2% |
| Dec 2025 | NT$13.2 million | -8.2% | +8.1% |
| Nov 2025 | NT$12.2 million | -23.4% | +6.7% |
| Oct 2025 | NT$11.5 million | -3.6% | -19.8% |
| Sep 2025 | NT$14.3 million | -32.3% | +7.9% |
| Aug 2025 | NT$13.2 million | -11.6% | +13.8% |
| Jul 2025 | NT$11.6 million | -40.9% | +11.8% |
| Jun 2025 | NT$10.4 million | -51.9% | -17.3% |
| May 2025 | NT$12.6 million | -37.7% | -19.9% |
| Apr 2025 | NT$15.7 million | -15.1% | +45.1% |
| Mar 2025 | NT$10.8 million | -40.8% | -48.7% |
| Feb 2025 | NT$21.1 million | +324.4% | +172.8% |
| Jan 2025 | NT$7.7 million | -43.7% | -46.2% |
| Dec 2024 | NT$14.4 million | -25.7% | -9.8% |
| Nov 2024 | NT$16 million | -23.9% | +34.3% |
| Oct 2024 | NT$11.9 million | -8.7% | -43.7% |
Jan–Oct 2026 cumulative: NT$153.1 million (+18.7% YoY)
Other Biotech & Medical companies
Compare with peers: Shangya Technology vs PEC / Shangya Technology vs Lotus Pharm / Shangya Technology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
藥品收入及加工收入增加
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16